Literature DB >> 28495453

Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization.

Ryan M Kiefer1, Stephen J Hunt2, Santiago Pulido1, Stephen Pickup3, Emma E Furth4, Michael C Soulen3, Gregory J Nadolski2, Terence P Gade5.   

Abstract

PURPOSE: To test the hypotheses that (i) heavier rats demonstrate improved survival with diminished fibrosis in a diethylnitrosamine (DEN)-induced model of hepatocellular carcinoma (HCC) and (ii) transarterial embolization via femoral artery access decreases procedure times versus carotid access.
MATERIALS AND METHODS: One hundred thirty-eight male Wistar rats ingested 0.01% DEN in water ad libitum for 12 weeks. T2-weighted magnetic resonance imaging was used for tumor surveillance. Rats underwent selective embolization of ≥ 5 mm tumors via carotid or femoral artery catheterization under fluoroscopic guidance. Rats were retrospectively categorized into 3 groups by initial weight (< 300, 300-400, > 400 g) for analyses of survival, tumor latency, and fibrosis. Access site was compared relative to procedural success, mortality, and time.
RESULTS: No significant differences in tumor latency were related to weight group (P = .310). Rats weighing < 300 g had shorter survival than both heavier groups (mean, 88 vs 108 d; P < .0001), and more severe fibrosis (< 300 g median, 4.0; 300-400 g median, 1.5; > 400 g median, 1.0; P = .015). No significant difference was found in periprocedural mortality based on access site; however, procedure times were shorter via femoral approach (mean, 71 ± 23 vs 127 ± 24 min; P < .0001).
CONCLUSIONS: Greater initial body weight resulted in improved survival without prolonged tumor latency for rats with DEN-induced HCCs and was associated with less severe fibrosis. A femoral approach for embolization resulted in decreased procedure time. These modifications provide a translational animal model of HCC and transarterial embolization that may be suited for short-term survival studies.
Copyright © 2017 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28495453      PMCID: PMC5593422          DOI: 10.1016/j.jvir.2017.03.037

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  24 in total

1.  Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations.

Authors:  Scott M Thompson; Matthew R Callstrom; Bruce Knudsen; Jill L Anderson; Rickey E Carter; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  J Vasc Interv Radiol       Date:  2012-01-20       Impact factor: 3.464

Review 2.  Immunological landscape and immunotherapy of hepatocellular carcinoma.

Authors:  Jesús Prieto; Ignacio Melero; Bruno Sangro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

3.  Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.

Authors:  Wei Zhang; Hui Juan Chen; Zhen J Wang; Wei Huang; Long Jiang Zhang
Journal:  Eur Radiol       Date:  2016-08-03       Impact factor: 5.315

4.  Mechanistic basis for nonlinearities and thresholds in rat liver carcinogenesis by the DNA-reactive carcinogens 2-acetylaminofluorene and diethylnitrosamine.

Authors:  G M Williams; M J Iatropoulos; A M Jeffrey
Journal:  Toxicol Pathol       Date:  2000 May-Jun       Impact factor: 1.902

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 6.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

7.  Targeted multimodal nano-reporters for pre-procedural MRI and intra-operative image-guidance.

Authors:  Joonseok Lee; Andrew C Gordon; Hacksung Kim; Wooram Park; Soojeong Cho; Byeongdu Lee; Andrew C Larson; Elena A Rozhkova; Dong-Hyun Kim
Journal:  Biomaterials       Date:  2016-09-19       Impact factor: 12.479

8.  Sprague-Dawley rats bearing McA-RH7777 cells for study of hepatoma and transarterial chemoembolization.

Authors:  Hye Rim Cho; Jin Woo Choi; Hyo-Cheol Kim; Yong Sub Song; Gyoung Min Kim; Kyu Ri Son; Jin Wook Chung
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

9.  Technical aspects of imaging and transfemoral arterial treatment of N1-S1 tumors in rats: an appropriate model to test the biology and therapeutic response to transarterial treatments of liver cancers.

Authors:  Shenghong Ju; Gordon McLennan; Stacy L Bennett; Yun Liang; Laurent Bonnac; Krzysztof W Pankiewicz; Hiremagalur N Jayaram
Journal:  J Vasc Interv Radiol       Date:  2009-01-23       Impact factor: 3.464

10.  Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.

Authors:  Karen T Brown; Richard K Do; Mithat Gonen; Anne M Covey; George I Getrajdman; Constantinos T Sofocleous; William R Jarnagin; Michael I D'Angelica; Peter J Allen; Joseph P Erinjeri; Lynn A Brody; Gerald P O'Neill; Kristian N Johnson; Alessandra R Garcia; Christopher Beattie; Binsheng Zhao; Stephen B Solomon; Lawrence H Schwartz; Ronald DeMatteo; Ghassan K Abou-Alfa
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

View more
  8 in total

1.  Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy.

Authors:  Nicholas R Perkons; Ryan M Kiefer; Michael C Noji; Mehrdad Pourfathi; Daniel Ackerman; Sarmad Siddiqui; David Tischfield; Enri Profka; Omar Johnson; Stephen Pickup; Anthony Mancuso; Austin Pantel; Michelle R Denburg; Gregory J Nadolski; Stephen J Hunt; Emma E Furth; Stephen Kadlecek; Terence P F Gade
Journal:  Hepatology       Date:  2020-05-16       Impact factor: 17.425

2.  Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer.

Authors:  Nicholas R Perkons; Omar Johnson; Gabrielle Pilla; Enri Profka; Michael Mercadante; Daniel Ackerman; Terence P F Gade
Journal:  Clin Cancer Res       Date:  2020-06-04       Impact factor: 12.531

3.  Woodchuck Hepatic Anatomy and Vascular Alterations Due to Hepatocellular Carcinoma with Angiographic Atlas of the Abdomen and Pelvis.

Authors:  Michal Mauda-Havakuk; Michael T Kassin; Andrew S Mikhail; Juan A Esparza-Trujillo; Ivane Bakhutashvili; David L Woods; Paul G Wakim; Matthew F Starost; John W Karanian; Bradford J Wood; William F Pritchard
Journal:  J Vasc Interv Radiol       Date:  2021-11-17       Impact factor: 3.464

4.  Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model.

Authors:  David J Tischfield; Alexey Gurevich; Omar Johnson; Isabela Gatmaytan; Gregory J Nadolski; Michael C Soulen; David E Kaplan; Emma Furth; Stephen J Hunt; Terence P F Gade
Journal:  Radiology       Date:  2022-01-11       Impact factor: 29.146

5.  An implanted port-catheter system for repeated hepatic arterial infusion of low-density lipoprotein-docosahexaenoic acid nanoparticles in normal rats: A safety study.

Authors:  Yuzhu Wang; Junjie Li; Indhumathy Subramaniyan; Goncalo Dias do Vale; Jaideep Chaudhary; Arnida Anwar; Mary Wight-Carter; Jeffrey G McDonald; William C Putnam; Tao Qin; Hongwei Zhang; Ian R Corbin
Journal:  Toxicol Appl Pharmacol       Date:  2020-05-15       Impact factor: 4.219

6.  B-mode ultrasound for the assessment of hepatic fibrosis: a quantitative multiparametric analysis for a radiomics approach.

Authors:  Julia C D'Souza; Laith R Sultan; Stephen J Hunt; Susan M Schultz; Angela K Brice; Andrew K W Wood; Chandra M Sehgal
Journal:  Sci Rep       Date:  2019-06-18       Impact factor: 4.379

7.  Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway.

Authors:  Wenbo Ding; Xiuwei Chen; Licheng Yang; Yaping Chen; Jie Song; Weiquan Bu; Bin Feng; Meng Zhang; Yi Luo; Xiaobin Jia; Liang Feng
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.279

8.  Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation.

Authors:  Caroline I Davis; Xingxing Gu; Ryan M Kiefer; Martina Ralle; Terence P Gade; Donita C Brady
Journal:  Metallomics       Date:  2020-12-23       Impact factor: 4.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.